Sunday, November 3, 2024

InsightRX Offers Precision Dosing Support for New Drug Categories

InsightRX, a precision dosing intelligence company, announced its expansion into three new therapeutic categories with the release of point-of-care dosing guidance for antifungal drugs, solid organ transplant drugs, and inflammatory bowel disease biologics. New modules of the company’s cloud-based precision dosing intelligence platform, InsightRX Nova, help clinicians rapidly achieve a therapeutic dosage and ensure continuity of care as patients transition from an inpatient setting to home, providing seamless support for outpatient therapeutic drug monitoring.

InsightRX Nova now offers modules for nearly every commercially available azole antifungal, including the highly sought after voriconazole and posaconazole. Azole antifungals are antibiotics used to treat disease caused by molds and yeast, which have a disproportionate impact on vulnerable and immunocompromised patients. The precision dosing platform uses patient-specific data, pharmacokinetic and pharmacodynamic models, and Bayesian forecasting to guide treatment decisions based on a patient’s unique pharmacological profile.

Also Read: New hygiene and health survey by Essity identifies the largest threats to the future of well-being

As measuring the toxicity and dosing efficacy of antifungals is challenging, they are often administered by clinicians with specialized expertise. The inclusion of these drugs within the InsightRX Nova platform removes barriers to treatment, enabling a broader group of clinicians to achieve the correct therapeutic exposure. As patients are likely to be on an antifungal regimen for months at a time, the platform’s oral and intravenous dose administration formulations support continuity of care through the patient’s transition from the hospital to an outpatient clinic. The voriconazole module can also incorporate available pharmacogenomic data, which indicates how quickly a patient metabolizes the drug, into its pharmacokinetic models to help clinicians dose appropriately.

InsightRX has also developed modules for a suite of solid organ transplant drugs, most notably tacrolimus, as well as mycophenolate, cyclosporine, and the mTOR inhibitors sirolimus and everolimus. For patients who have received solid organ transplants of the lungs, heart, liver, intestines, or kidney, these immunosuppressive medications prevent the patient’s body from rejecting the transplanted organ. InsightRX Nova helps clinicians rapidly achieve the appropriate therapeutic exposure in the perioperative period, which is key to the patient’s discharge from the hospital. Once the patient is stable, an outpatient dosing mode helps clinicians continue monitoring the patient’s dosing regimen.

“We’re excited to help clinicians improve patient outcomes by bringing predictive model-informed precision dosing to these new areas,” said Ron Keizer, PharmD, PhD, Chief Scientific Officer and co-founder of InsightRX. “Our precision dosing platform is always learning from incoming patient data, which enables us not only to pinpoint an optimal dose for each patient, but also to refine our pharmacokinetic and pharmacodynamic models over time, adding to this growing field of research.”

Subscribe Now

    Hot Topics